Looked at JGBO's Rodman & Renshaw's presentation...
and listened to Elsa's presentation.
As usual Elsa's presentation are off to a rough start. Things that caught my attention are;
1. Shares outstanding 11.1 million
2. Shares outstanding fully diluted over 17 million
3. No mention of uplisting. Why?
4. All the numbers appear strong
5. Lalyang Pear cough syrup 6.1% sales growing fast
Long Vester, maybe you could help us out here, I and many others still don't understand, with Jiangbo's great revenues, why would Cao except a convertible debenture that would almost double the amount of shares for just $35 million? Seems rather foolish, however, I remember you saying that this would probably never happen. Can you explain?
Jiangbo was the last presentation of the day. Not very good placement as compared to all the rest of the companies.
I'm planning to spend some time to investigate the requirements for uplisting. I just wanted doublecheck to make sure were eligible and that there's not some hidden problem. They very easily could have mentioned the uplisting since they've already mentioned in past press releases. Just a statement saying "we still plan on uplisting soon" would not be out of the ordinary.
But I don't know anything. Go Jiangbo!
Bigplay 777
